<DOC>
	<DOCNO>NCT00030771</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel cisplatin , use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving chemotherapy radiation therapy surgery may make tumor small reduce amount normal tissue need remove . It yet know chemotherapy plus radiation therapy effective chemotherapy alone surgery treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study docetaxel cisplatin without radiation therapy see well work give surgery treat patient stage IIIA non-small cell lung cancer spread lymph node chest .</brief_summary>
	<brief_title>Preoperative Chemoradiotherapy v . Chemotherapy Alone NSCLC Patients</brief_title>
	<detailed_description>The main objective trial compare feasibility efficacy sequential neoadjuvant chemoradiotherapy 44 Gy concomitant boost neoadjuvant chemotherapy alone . Secondary objective ass value PET predict pathological response eventfree survival stage IIIA NSCLC , health economic analysis two regimen . Further compare amount serum DNA patient stage IIIA , pN2 NSCLC chemotherapy , surgery second follow-up visit ( i.e . four month surgery treatment failure patient operate ) patient randomize trial SAKK 16/00 correlate DNA variation tumor response , remission duration overall survival . OUTLINE : This prospective randomized phase III trial . Patients stratify accord mediastinal bulk ( 5 cm v le 5 cm ) , weight loss past 6 month ( 5 % v le 5 % ) , participate center . Patients randomize 1 2 treatment arm .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Squamous , adenosquamous , large cell , poorly differentiate Stage IIIA ( T13 , N2 , M0 ) N2 disease confirm 1 following : Mediastinoscopy Bronchoscopy fineneedle aspiration esophagoscopy All N3 lymph node must negative positronemission tomography ( PET ) AND CT scan ( &lt; 1 cm large diameter ) PET scan Both primary tumor least 1 N2 lymph node must positive PET scan At least 1 PET scan positive N2 lymph node positive CT scan ( &gt; 1 cm large diameter ) All N3 lymph node negative PET scan PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST/ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Creatinine clearance great 60 mL/min Cardiovascular : Cardiac function normal No unstable cardiac disease require treatment No congestive heart failure No angina pectoris even medically control No significant arrhythmia No myocardial infarction past 3 month Pulmonary : Lung function appropriate Neurologic : No history significant neurologic psychiatric disorder No psychotic disorder No dementia No seizures Other : No prior concurrent malignancy except nonmelanoma skin cancer , adequately treat carcinoma situ cervix , neoplastic disease diseasefree interval â‰¥ 5 year No active uncontrolled infection No uncontrolled diabetes mellitus No gastric ulcer No preexist peripheral neuropathy great grade 1 No contraindication corticosteroids No serious underlie medical condition would preclude study participation No socioeconomic geographic condition would preclude study participation Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytostatic chemotherapy Endocrine therapy : No concurrent prednisone except treatment acute hypersensitivity reaction chronic lowdose treatment initiate 6 month prior study entry ( i.e. , great 20 mg methylprednisolone equivalent ) Radiotherapy : No prior radiotherapy chest Surgery : Not specify Other : At least 30 day since participation another clinical study No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>